AV
AVIR.O
—
NASDAQ
Pharmaceuticals & Medical Research
Atea Pharmaceuticals Inc
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
-57,5 %
Net margin
—
Debt / equity
0,00
Beta
—
52w range
—
Volume
1
Day range
—
Prev close
$4,53
Open
—
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
Atea Pharmaceuticals Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of antiviral therapies, primarily targeting viral infections such as hepatitis B and C, as well as emerging viral threats.
Business. Atea Pharmaceuticals Inc is a health care company operating in the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ under the ticker symbol AVIR. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
FMR LLC
largest disclosed fund holder
Profitability→
-57,5 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to AVIR.O. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Atea Pharmaceuticals Inc is a health care company operating in the pharmaceuticals and medical research industry. The firm is headquartered in the United States and is primarily listed on the NASDAQ under the ticker symbol AVIR. Specific details regarding operating segments and geographic revenue mix are not available.
Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
AI synthesis
GENERATEDAtea Pharmaceuticals Inc has a capital structure characterized by a debt-to-equity ratio of 0.0, indicating no long-term debt obligations. The company maintains a strong liquidity position with a current ratio of 7.82, supported by $95.7 million in cash and equivalents. However, the company reported negative operating and free cash flows of -$132.0 million and -$157.9 million, respectively, reflecting ongoing operational cash outflows.
Profitability metrics show significant underperformance relative to industry norms. The company reported a return on equity (ROE) of -57.49% and a return on assets (ROA) of -50.23%, both of which are well below the typical thresholds for biotechnology firms. These negative returns suggest that the company is not generating value for shareholders or effectively utilizing its assets to generate profit.
Atea Pharmaceuticals Inc operates in a single business segment focused on antiviral therapies, with no disclosed geographic revenue concentration. The company's revenue is primarily derived from its pipeline of antiviral drugs, including clinical-stage candidates for hepatitis B and C, as well as other viral threats. The lack of geographic diversification and reliance on a narrow product pipeline increases the company's exposure to clinical and regulatory risks.
The company's growth trajectory is constrained by its current financial position. With no disclosed revenue history and ongoing losses, Atea Pharmaceuticals Inc is not currently generating revenue from commercial products. The company is in the development phase, and its future growth will depend on the successful advancement of its drug candidates through clinical trials and regulatory approval.
Risk factors for Atea Pharmaceuticals Inc include the high costs and uncertainties associated with drug development, the competitive landscape in the biotechnology sector, and the potential for regulatory delays or rejections. The company has not disclosed any immediate dilution risks, with a low dilution score and no filing-based flags indicating potential equity issuance. However, the company's reliance on external financing to fund operations could increase the likelihood of future dilution if clinical or regulatory milestones are not met.
Recent events include the company's continued focus on its lead candidate, ATE404, for the treatment of chronic hepatitis B. Atea has also expanded its pipeline to include preclinical programs targeting other viral diseases. The company has not disclosed any recent major filings or earnings transcripts that would indicate significant changes in its strategic direction or financial outlook.
Key takeaways
- Atea Pharmaceuticals Inc is a biopharmaceutical company with a focus on antiviral therapies, currently in the development phase with no commercial products.
- The company has a strong liquidity position with $95.7 million in cash and equivalents but is experiencing negative operating and free cash flows.
- Atea's profitability metrics are significantly negative, with a return on equity of -57.49% and a return on assets of -50.23%.
- The company operates in a single business segment with no geographic diversification, increasing its exposure to clinical and regulatory risks.
- Atea has no immediate dilution risks, but its reliance on external financing could lead to future equity issuance if development milestones are not met.
- The company's growth is contingent on the successful advancement of its drug candidates through clinical trials and regulatory approval.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$4,61
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$275.4M
Net cashⓘ
$95.7M
Current ratioⓘ
7.8
Debt / equityⓘ
0.0
ROAⓘ
-50.2%
ROEⓘ
-57.5%
Cash conversionⓘ
83.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures
Partners2
MERCK & CO., INC.MRK.OPartner95%Source ↗
GILEAD SCIENCES, INC.GILD.OPartner90%Source ↗
Supply chain
Vendors → AVIR ↔ Partners → Customers · click any node to drill
2 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-06-24Peer comparison
Peer comparison7 peers · vs AVIR · multiples and returns
KL
KLAR—
KLAR.ST
—
—P/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
BN
BNTX—
Biontech SE
$92,25
23,3B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
—
— vs self
EX
EXEL—
Exelixis Inc
$55,06
14,7B USDP/E
19,5x
— vs self
Div yield
—
— vs self
ROE
40,4 %
+97,9 vs self
MD
MDGL—
Madrigal Pharmaceuticals Inc
$482,00
11,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-47,8 %
+9,7 vs self
IN
INSM—
Insmed Inc
$107,46
23,0B USDP/E
—
— vs self
Div yield
—
— vs self
ROE
-160,2 %
-102,7 vs self
VC
VCYT—
Veracyte Inc
$45,30
3,6B USDP/E
55,5x
— vs self
Div yield
—
— vs self
ROE
5,1 %
+62,6 vs self
MD
MDXG—
Mimedx Group Inc
$4,27
636,0M USDP/E
11,1x
— vs self
Div yield
—
— vs self
ROE
18,9 %
+76,4 vs self
Market position
Stress test
— missing data
Predictor forecast
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution3 analysts
Strong buy1
Buy1
Hold1
Sell0
Strong sell0
12-month price target$10,00 · Median $10,00
Low $10,00High $10,00
Operating income · consensus-164,5M USD
EPS surprise
−16,9 %
reported vs consensus · miss
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$10,00
Mean$10,00
Median$10,00
High$10,00
Spot$4,61
+116.9 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskLow
Filing-based flags
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
ROE-57,5 %Below median
D/E0,00Above median
Cash Conv0,83Above median
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net acquired 335 022 sh20 exercises · 21 grants14 insiders
- Director · Restricted Stock Units → Common StockAcquired 26 700grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 37 700 @ $4,36grant · 2026-06-18
- Director · Restricted Stock Units → Common StockDisposed 29 600exercise · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 26 700grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 37 700 @ $4,36grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 26 700grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 37 700 @ $4,36grant · 2026-06-18
- Director · Restricted Stock Units → Common StockDisposed 29 600exercise · 2026-06-18
- Director · Restricted Stock Units → Common StockDisposed 29 600exercise · 2026-06-18
- Director · Restricted Stock Units → Common StockDisposed 29 600exercise · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 26 700grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 37 700 @ $4,36grant · 2026-06-18
- Director · Restricted Stock Units → Common StockDisposed 29 600exercise · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 26 700grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 37 700 @ $4,36grant · 2026-06-18
- Director · Restricted Stock Units → Common StockDisposed 29 600exercise · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 26 700grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 37 700 @ $4,36grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 26 700grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 37 700 @ $4,36grant · 2026-06-18
- Director · Restricted Stock Units → Common StockAcquired 26 700grant · 2026-06-18
- Director · Stock Option (Right to Buy) → Common StockAcquired 37 700 @ $4,36grant · 2026-06-18
- See Remarks · Stock Option (Right to Buy) → Common StockAcquired 60 000 @ $1,24exercise · 2026-03-11
- Director, President, CEO, and Chairman · Stock Option (Right to Buy) → Common StockDisposed 300 000 @ $1,24exercise · 2026-02-03
- See Remarks · Restricted Stock Units → Common StockDisposed 10 500exercise · 2026-01-31
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
Source documents
- Atea Pharmaceuticals Inc Market data — financials · 2026-05-27
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,00 %$64M
- Investment Managers · as of 2026-03-310,00 %$7M
- Investment Managers · as of 2024-06-300,00 %$30M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$9M
- Investment Managers · as of 2024-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$4M
- Investment Managers · as of 2025-12-310,00 %$15M
- Institutional Investor · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Funds · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Institutional Investor · as of 2026-03-310,00 %$0M
Insider activity
Mixed / flat0 buys · 0 sellsnet $012 insiders · last 365d
- Director · Common StockOther 29 600 · 2026-06-18
- Director · Common StockOther 29 600 · 2026-06-18
- Director · Common StockOther 29 600 · 2026-06-18
- Director · Common StockOther 29 600 · 2026-06-18
- Director · Common StockOther 29 600 · 2026-06-18
- Director · Common StockOther 29 600 · 2026-06-18
- See Remarks · Common StockOther 60 000 @ $1,24$74K · 2026-03-11
- Director, President, CEO, and Chairman · Common StockOther 300 000 @ $1,24$372K · 2026-02-03
- EVP, Chief Accounting Officer · Common StockOther 41 333 · 2026-01-31
- Chief Medical Officer · Common StockOther 51 283 · 2026-01-31
- Chief Medical Officer · Common StockOther 16 073 @ $4,24$68K · 2026-01-31
- Chief Commercial Officer · Common StockOther 42 083 · 2026-01-31
- Chief Commercial Officer · Common StockOther 11 570 @ $4,24$49K · 2026-01-31
- Chief Development Officer · Common StockOther 58 050 · 2026-01-31
- Chief Development Officer · Common StockOther 14 136 @ $4,24$60K · 2026-01-31
- See Remarks · Common StockOther 54 866 · 2026-01-31
- See Remarks · Common StockOther 16 104 @ $4,24$68K · 2026-01-31
- Director, President, CEO, and Chairman · Common StockOther 272 983 · 2026-01-31
- Director, President, CEO, and Chairman · Common StockOther 106 093 @ $4,24$450K · 2026-01-31
- EVP, Chief Accounting Officer · Common StockOther 12 132 @ $4,24$51K · 2026-01-31
Short positioning
7.8Mshares short+11.0% vs prior
22.75days to cover
66.3%short of daily vol
164fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
AVIR.OCanonical
NASDAQ · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskLow
No immediate filing-based liquidity or dilution flags were detected.
Relationship graph
This companySectorPartners
Evidence & claims
From filings & derived data- Current ratio (FY 2025-12-31): 7.82xDerived (calculated)
- Return on equity (FY 2025-12-31): -57.4%Derived (calculated)
- Return on assets (FY 2025-12-31): -50.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 47.9%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 3.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 3.0%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 6.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 2.6%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 6.3%Derived (calculated)
- Debt-to-equity (FY 2025-12-31): 0.14xDerived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 2.7%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -37.2%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -32.2%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 54.2%Derived (calculated)
- EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
- Total assets (annual): USD 315.22MSEC XBRL filing
- Operating income (annual): USD -180.89MSEC XBRL filing
- Current assets (annual): USD 310.99MSEC XBRL filing
- Pre-tax income (annual): USD -164.51MSEC XBRL filing
- Shares outstanding (annual): 78.13MSEC XBRL filing
- Current liabilities (annual): USD 39.78MSEC XBRL filing
- Shareholders' equity (annual): USD 275.43MSEC XBRL filing
- Net income (annual): USD -158MSEC XBRL filing
- Total operating expenses (annual): USD 180.89MSEC XBRL filing
Showing 24 of 46 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-06-18 00:00 UTCINSIDER28 insider transactions — 2026-06 22 derivative
2026-06-18INSIDERMurphy Polly A. transacted 29.6k sh — Director
2026-06-18INSIDERAdams Jerome M. transacted 29.6k sh — Director
2026-06-18INSIDERDUNCAN BARBARA GAYLE transacted 29.6k sh — Director
2026-06-18INSIDERLucidi Bruno transacted 29.6k sh — Director
2026-06-18INSIDERBERGER FRANKLIN M transacted 29.6k sh — Director
2026-06-18INSIDERPolsky Bruce transacted 29.6k sh — Director
2026-06-18INSIDERBERGER FRANKLIN M disposed of 29.6k sh Restricted Stock Units — Director
2026-06-18INSIDERDUNCAN BARBARA GAYLE disposed of 29.6k sh Restricted Stock Units — Director
2026-06-18INSIDERLucidi Bruno acquired 37.7k sh Stock Option (Right to Buy) — Director
2026-06-18INSIDERBerman Howard acquired 37.7k sh Stock Option (Right to Buy) — Director
2026-06-18INSIDERLucidi Bruno disposed of 29.6k sh Restricted Stock Units — Director
2026-06-18INSIDERLucidi Bruno acquired 26.7k sh Restricted Stock Units — Director
2026-06-18INSIDERBerman Howard acquired 26.7k sh Restricted Stock Units — Director
2026-06-18INSIDERBERGER FRANKLIN M acquired 37.7k sh Stock Option (Right to Buy) — Director
2026-06-18INSIDERBERGER FRANKLIN M acquired 26.7k sh Restricted Stock Units — Director
2026-06-18INSIDERPolsky Bruce acquired 26.7k sh Restricted Stock Units — Director
2026-06-18INSIDERDUNCAN BARBARA GAYLE acquired 37.7k sh Stock Option (Right to Buy) — Director
2026-06-18INSIDERDUNCAN BARBARA GAYLE acquired 26.7k sh Restricted Stock Units — Director
2026-06-18INSIDERAdams Jerome M. acquired 26.7k sh Restricted Stock Units — Director
2026-06-18INSIDERAdams Jerome M. acquired 37.7k sh Stock Option (Right to Buy) — Director
2026-06-18INSIDERKIRSCH ARTHUR S acquired 26.7k sh Restricted Stock Units — Director
2026-06-18INSIDERAdams Jerome M. disposed of 29.6k sh Restricted Stock Units — Director
2026-06-18INSIDERKIRSCH ARTHUR S acquired 37.7k sh Stock Option (Right to Buy) — Director
2026-06-18INSIDERMurphy Polly A. acquired 37.7k sh Stock Option (Right to Buy) — Director
2026-06-18INSIDERMurphy Polly A. acquired 26.7k sh Restricted Stock Units — Director
2026-06-18INSIDERMurphy Polly A. disposed of 29.6k sh Restricted Stock Units — Director
2026-06-18INSIDERPolsky Bruce acquired 37.7k sh Stock Option (Right to Buy) — Director
2026-06-18INSIDERPolsky Bruce disposed of 29.6k sh Restricted Stock Units — Director
2026-03-11 00:00 UTCINSIDER2 insider transactions — 2026-03 1 derivative
2026-03-11INSIDERCorcoran Andrea transacted 60.0k sh — See Remarks ~$74k
2026-03-11INSIDERCorcoran Andrea acquired 60.0k sh Stock Option (Right to Buy) — See Remarks
2026-02-03 00:00 UTCINSIDER2 insider transactions — 2026-02 · net buy $372k 1 derivative
2026-02-03INSIDERSommadossi Jean-Pierre transacted 300.0k sh — Director, President, CEO, and Chairman ~$372k
Showing the 40 most recent of 60 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage